Scarica l'app Stockscreener
1.21
1.63%
-0.02
Dopo l'orario di chiusura:
1.23
0.02
+1.65%
Precedente Chiudi:
$1.23
Aprire:
$1.225
Volume 24 ore:
154.28K
Relative Volume:
0.49
Capitalizzazione di mercato:
$27.06M
Reddito:
-
Utile/perdita netta:
$-16.51M
Rapporto P/E:
-0.8944
EPS:
-1.3528
Flusso di cassa netto:
$-15.68M
1 W Prestazione:
-11.68%
1M Prestazione:
-22.68%
6M Prestazione:
-58.70%
1 anno Prestazione:
-53.46%
Intervallo 1D:
$1.16
$1.25
Intervallo di 1 settimana:
$1.14
$1.48
Portata 52W:
$1.14
$8.94
Medicus Pharma Ltd Stock (MDCX) Company Profile
Nome
Medicus Pharma Ltd
Settore
Industria
Telefono
610-540-7515
Indirizzo
300 CONSHOHOCKEN STATE RD., W. CONSHOHOCKEN
Confronta MDCX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MDCX
Medicus Pharma Ltd
|
1.21 | 27.51M | 0 | -16.51M | -15.68M | -1.3528 |
|
LLY
Lilly Eli Co
|
1,039.51 | 951.18B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
224.44 | 533.63B | 94.19B | 26.80B | 20.46B | 11.05 |
|
ABBV
Abbvie Inc
|
223.93 | 390.19B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
NVS
Novartis Ag Adr
|
152.22 | 286.13B | 54.45B | 14.42B | 17.15B | 7.333 |
|
NVO
Novo Nordisk Adr
|
62.89 | 284.29B | 46.69B | 15.29B | 9.25B | 3.4329 |
Medicus Pharma Ltd Borsa (MDCX) Ultime notizie
Earnings Update: Is Medicus Pharma Ltd Equity Warrant subject to activist investor interest2025 Bull vs Bear & AI Optimized Trading Strategy Guides - baoquankhu1.vn
Medicus Pharma - The Pharma Letter
Medicus Pharma to acquire Antev - MSN
Medicus Pharma Ltd. Announces Engagement With Reliant AI to Develop Artificial Intelligence (AI) Driven Clinical Data Analytics Platform - progress-index.com
Aug Analyst Calls: Is SCOR stock undervalued right nowJuly 2025 Action & Verified Swing Trading Watchlists - baoquankhu1.vn
Medicus Pharma Ltd. Provides Corporate Updates and Reports Third Quarter 2025 Financial Highlights - coloradoan.com
Medicus Pharma Ltd. Receives Full United Kingdom Regulatory and Ethical Approvals To Expand Phase 2 Clinical Study (SKNJCT-003) To Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin - hattiesburgamerican.com
Medicus Pharma Lowers Teverelix Royalty Burden in Amended LifeArc License - TipRanks
Medicus Pharma Marks Nasdaq Anniversary With Opening Bell Ceremony - The National Law Review
Small cap wrap: Medicus Pharma, OKYO, American Resources... - Proactive financial news
Moving Averages: Does Medicus Pharma Ltd Equity Warrant align with a passive investing strategyJuly 2025 Volume & Low Risk High Reward Ideas - baoquankhu1.vn
Bell Rings on Wall Street as Medicus Marks One Year as Nasdaq Player - mychesco.com
Medicus Pharma marks Nasdaq milestone as it advances Phase 2 clinical programs - Proactive Investors
Medicus Pharma reduces royalty rate on Teverelix to 2 percent By Investing.com - Investing.com Nigeria
Medicus Pharma reduces royalty rate on Teverelix to 2 percent - Investing.com
Medicus Pharma marks Nasdaq anniversary with opening bell ceremony - Proactive financial news
Medicus Pharma Ltd. Rings the Opening Bell - Nasdaq
Medicus Pharma lowers royalty burden on prostate cancer drug Teverelix - Proactive financial news
Market movers: GE Aerospace, Mobileye, Medicus Pharma, P&G... - Proactive financial news
Medicus Pharma Ltd. Announces Amendment to LifeArc License Improving Teverelix® Long-Term Economic and Development Profile - The Manila Times
Medicus Pharma Ltd. Announces Amendment to LifeArc License - GlobeNewswire
Risk Analysis: Is RYAAY in a long term uptrendJuly 2025 PreEarnings & Verified Trade Idea Suggestions - baoquankhu1.vn
Medicus Pharma marks one-year Nasdaq anniversary, advances Phase 2 therapeutics - Proactive financial news
Medicus Pharma to Ring Nasdaq Opening Bell on January 22, 2026, Celebrating One-Year Anniversary - Intellectia AI
Medicus Pharma Rings Nasdaq Opening Bell to Celebrate One-Year Listing Anniversary - Intellectia AI
Medicus Pharma Ltd. Celebrates One Year on Nasdaq with Opening Bell Ceremony on January 22, 2026 - marketscreener.com
Block Trades: Can Medicus Pharma Ltd Equity Warrant lead its sector in growthJuly 2025 Weekly Recap & Community Consensus Trade Alerts - baoquankhu1.vn
Wall Street Recap: Does Medicus Pharma Ltd Equity Warrant meet Warren Buffetts criteriaFed Meeting & Daily Growth Stock Investment Tips - baoquankhu1.vn
Guidance Update: Is Medicus Pharma Ltd Equity Warrant a speculative investmentWeekly Profit Report & High Return Trade Opportunity Guides - baoquankhu1.vn
Medicus Pharma to Present Women’s Teverelix Data as SkinJect Phase 2 Approaches Database Lock - Proactive financial news
EV Market: Can Medicus Pharma Ltd sustain its profitabilityMarket Risk Report & Precise Swing Trade Entry Alerts - baoquankhu1.vn
Risk Off: Will Prime Medicine Inc stock hit new highs in YEARJuly 2025 WrapUp & Smart Money Movement Tracker - baoquankhu1.vn
Medicus Pharma’s warrant inducement agreement announced - MSN
Aug Levels: Will Medicus Pharma Ltd Equity Warrant benefit from rising consumer demandJuly 2025 Movers & Weekly Top Gainers Trade List - baoquankhu1.vn
Decliners Report: What is the cash position of Corteva Inc2025 Technical Overview & Fast Gaining Stock Reports - baoquankhu1.vn
Market Pulse: Can Tantech Holdings Ltd expand its profit margins2025 Valuation Update & Precise Trade Entry Recommendations - baoquankhu1.vn
Stock Report: Will Medicus Pharma Ltd Equity Warrant benefit from seasonalityJuly 2025 Drop Watch & Proven Capital Preservation Tips - baoquankhu1.vn
Fundamentals Check: Is Medicus Pharma Ltd likely to announce a buybackMarket Growth Review & Target Return Focused Picks - baoquankhu1.vn
Medicus Pharma’s teverelix data accepted for presentation at AACE 2026 By Investing.com - Investing.com Nigeria
Medicus Pharma’s Teverelix shows positive efficacy and safety in premenopausal women - Pharmafile
Analyst Upgrade: Why is Medicus Pharma Ltd stock going downMarket Trend Summary & Proven Capital Preservation Methods - baoquankhu1.vn
Small cap wrap: Digi Power X, C3 Metals, Medicus Pharma, EDM Resources... - Proactive financial news
Medicus Pharma advances Teverelix program, set to present Phase 1 data at AACE Annual Meeting - Proactive financial news
Medicus Pharma Highlights Positive Teverelix Phase 1 Data and Near-Term SkinJect Milestones - TipRanks
Medicus Pharma’s teverelix data accepted for presentation at AACE 2026 - Investing.com
Medicus Pharma Ltd. Studies Demonstrate Long-Acting Therapeutic Approach with Stable Bone Turnover in Women - The Manila Times
Medicus Pharma Ltd. Announces Collaboration with the Gorlin Syndrome Alliance to Pursue Compassionate Use Pathway for Skinject(TM) in Patients with Gorlin Syndrome - hattiesburgamerican.com
Medicus Pharma Ltd. Strengthens Leadership and Expands Clinical Trials - MSN
Medicus Pharma Shakes Up Executive Ranks as President Takes on CFO Role - MSN
Medicus Pharma Ltd Azioni (MDCX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.34%
1.70%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):